Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on July 9, 2021, regarding events occurring at its Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol NRBO.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Voting Results
The filing details the outcomes of two proposals voted on by stockholders. A total of 16,804,185 shares were represented at the meeting out of 22,285,492 shares outstanding.
Proposal 1: Election of Directors
Three Class II directors were elected to serve three-year terms until the 2024 annual meeting:
- Jason Groves: 13,324,509 votes for; 2,572,186 votes withheld.
- Hyung Heon Kim: 13,452,207 votes for; 2,444,488 votes withheld.
- Andrew Koven: 15,887,693 votes for; 9,002 votes withheld.
Proposal 2: Ratification of Auditors
Stockholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 15,885,134
- Votes Against: 914,566
- Votes Abstain: 4,485
Management Commentary, Risks, and Contingencies
In connection with the election of Mr. Koven and Mr. Kim, the Company will enter into standard indemnification agreements. These agreements may require the Company to indemnify the directors for expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from their service to the Board. A press release dated July 12, 2021, announcing these elections is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the correct registrant name is NeuroBo Pharmaceuticals, Inc. (NRBO), not Metavia Inc.
- Confirm the specific vote counts for the newly elected directors, noting the significant number of votes withheld for Jason Groves and Hyung Heon Kim compared to Andrew Koven.
- Review the attached press release (Exhibit 99.1) for additional context on the new board members' backgrounds.
- Check subsequent filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K contains none.